Literature DB >> 10622566

Hepatitis C virus infection in Eastern Europe.

N V Naoumov1.   

Abstract

UNLABELLED: This analysis aims to summarise the available information on the incidence, prevalence and characteristics of hepatitis C virus (HCV) infection in countries in Eastern Europe.
METHODS: A questionnaire was prepared on the epidemiology and diagnosis of HCV infection and sent to national experts in the field. Further information was obtained from publications in international and national scientific journals. The incidence of acute hepatitis C in different countries for 1997 varied between 2.3 and 9.0 per 100 000 population with a trend towards increasing numbers of cases in several countries over the last few years. The prevalence of anti-HCV in blood donors ranged between 0.7% and 4.9%. The most frequent routes of transmission of HCV appear to be diagnostic and therapeutic procedures in the health care setting and/or intravenous drug use. Cumulative data on HCV genotype distribution based on 1774 patients demonstrate a large predominance of genotype 1b, which is found in between 51% and 92% of patients with HCV infection. There is a high prevalence of HCV infection in Eastern Europe. Further studies with larger groups of patients and especially including molecular diagnostic assays are needed to better define the characteristics of HCV infection, its natural course and the impact of host and viral factors on the HCV-induced liver diseases. These will have a major role for adequate selection and monitoring of the patients' treatment.

Entities:  

Mesh:

Year:  1999        PMID: 10622566     DOI: 10.1016/s0168-8278(99)80380-8

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  14 in total

Review 1.  Treatment of hepatitis C. The 2002 French consensus.

Authors:  D Dhumeaux; P Marcellin; E Lerebours
Journal:  Gut       Date:  2003-12       Impact factor: 23.059

2.  Nested restriction site-specific PCR to detect and type hepatitis C virus (HCV): a rapid method to distinguish HCV subtype 1b from other genotypes.

Authors:  L Krekulova; V Rehak; A E Wakil; E Harris; L W Riley
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

3.  Infectious disease comorbidities adversely affecting substance users with HIV: hepatitis C and tuberculosis.

Authors:  Gerald Friedland
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12       Impact factor: 3.731

4.  Known and probable risk factors for hepatitis C infection: a case series in north-eastern Poland.

Authors:  Sławomir Chlabicz; Robert Flisiak; Anna Grzeszczuk; Oksana Kovalchuk; Danuta Prokopowicz; Lech Chyczewski
Journal:  World J Gastroenterol       Date:  2006-01-07       Impact factor: 5.742

5.  Hepatitis C virus infection among drug injectors in St Petersburg, Russia: social and molecular epidemiology of an endemic infection.

Authors:  Elijah Paintsil; Sergei V Verevochkin; Elena Dukhovlinova; Linda Niccolai; Russell Barbour; Edward White; Olga V Toussova; Louis Alexander; Andrei P Kozlov; Robert Heimer
Journal:  Addiction       Date:  2009-08-27       Impact factor: 6.526

Review 6.  Molecular and contextual markers of hepatitis C virus and drug abuse.

Authors:  Paul Shapshak; Charurut Somboonwit; Lydia N Drumright; Simon D W Frost; Deborah Commins; Timothy L Tellinghuisen; William K Scott; Robert Duncan; Clyde McCoy; J Bryan Page; Brian Giunta; Francisco Fernandez; Elyse Singer; Andrew Levine; Alireza Minagar; Oluwadayo Oluwadara; Taiwo Kotila; Francesco Chiappelli; John T Sinnott
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

Review 7.  Epidemiology and natural history of HCV infection.

Authors:  Behzad Hajarizadeh; Jason Grebely; Gregory J Dore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-07-02       Impact factor: 46.802

Review 8.  Acute hepatitis C: management in the rapidly evolving world of HCV.

Authors:  Suraj A Sharma; Jordan J Feld
Journal:  Curr Gastroenterol Rep       Date:  2014-02

9.  Impaired renal allograft, but not patient survival, in patients with antibodies to hepatitis C virus.

Authors:  L Giblin; M R Clarkson; P J Conlon; J J Walshe; P O'Kelly; D Hickey; D Little; M Keoghan; J Donohoe
Journal:  Ir J Med Sci       Date:  2004 Apr-Jun       Impact factor: 1.568

10.  Anti-HCV prevalence in the general population of Lithuania.

Authors:  Valentina Liakina; Jonas Valantinas
Journal:  Med Sci Monit       Date:  2012-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.